Tuesday, 25 Feb 2020

You are here

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

The FDA panel hearing was prompted by earlier studies that resulted in a July 2018 complete response letter for CV safety concerns. Panelists expressed concerns about the safety data, but nonetheless favored drug approval based on impressive efficacy data.  Most called for more post-marketing studies to further evaluate the long-term safety.

The FDA and sponsor presented data proving the effectiveness of romosozumab in postmenopausal osteoporosis, reducing vertebral fracture risk and trending towards a lower risk of non-vertebral fractures. 

Evenity, chemically known as romosozumab, belongs to a new class of drugs known as sclerostin inhibitors and is administered as a monthly subcutaneous injection. 

The FDA is not mandated to follow the recommendation of the panel, but generally does.

The meeting agenda, panel list and briefing documents can be found at the FDA website.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

FDA approved  romosozumab .it inhibits sclerostin .as all of us know, physiologically sclerostin inhibits WNT signaling pathway. Physiologically WNT signaling pathway leads to increased bone formation.now when we inhibit sclerostin to treat osteoporosis,inhibition of WNT signaling pathway will be removed that leads to increased bone formation and it will be worsen osteophyte formation  in osteoarthritic patients...
Osteonabolic agents most notably Romosuzumab not generally recommended as the first line for the treatment of osteoporosis, because of their substantial cost.Osteoanabolic treatment recommended in following individuals: (1) severe osteoporosis with high risk of fracture, (2) treatment failure with alternative osteoporosis agents with good adherent to treatment ( BMD loss or Fx), (3) contraindications or intolerance to other osteoporosis agents, and (4) GIOP..

More Like This

JAK Inhibitors Stimulate Osteoblasts

Science Translational Medicine has a report on how the use of Janus kinase (JAK) inhibitors may boost osteoblasts to battle bone erosions in conditions like rheumatoid arthritis (RA).

JAK inhibitors have been shown in clinical trials to retard the development of bone erosions while controlling RA inflammation and other clinical features.

Hormone Therapy for Postmenopausal Women

The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?

Knee Replacements Last 25 Years

UK registry reports that greater than 80% of total knee replacements can last for 25 years.

The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial.